Quick Answer
Reishi (Ganoderma lucidum, “Lingzhi”) is best viewed as a specialized tool, not a cure-all. In an 8-week randomized trial for neurasthenia, a reishi polysaccharide extract improved fatigue and sense of well-being compared with placebo (Tang et al., 2005). But a rigorous 16-week RCT found no meaningful improvements in glucose or lipids in type 2 diabetes and metabolic syndrome (Klupp et al., 2016). Rare liver injury reports mean quality, screening, and monitoring matter (LiverTox, 2024).
Trust Signal
By Superfood Science Writing Team | Updated 2026 | Evidence-informed, conservative claims
Key Takeaways
· Reishi’s clearest human signal is improved fatigue and well-being in a specific 8-week RCT population (Tang et al., 2005).
· For blood sugar, cholesterol, and metabolic claims, the best-quality RCT evidence is a reality check (Klupp et al., 2016).
· Some reviews describe hepatoprotective mechanisms in preclinical studies, but human liver-disease outcomes are not established (Ahmad et al., 2023).
· Because rare liver injury has been reported, a pro-reishi approach means using guardrails: choose quality products, avoid stacking, start conservatively, and monitor appropriately (LiverTox, 2024).
Reishi Is Everywhere—So What Does the Science Actually Say?
Reishi has become a modern symbol of calm and focus. Teas, tinctures, capsules, and latte add-ins often position it as the Queen of Mushrooms. The human evidence is more specific. Reishi appears most promising for certain fatigue-and-well-being profiles, whereas cardiometabolic claims are not reliably supported by rigorous trials (Tang et al., 2005; Klupp et al., 2016).
Why Reishi Is Studied and Why Results Vary
Reishi products are often described by two compound families: polysaccharides, which are commonly linked to immune signaling, and triterpenes, which are often linked to stress-response pathways in mechanistic research. A practical caveat is that “reishi” is not one standardized ingredient. Fruiting body, spores, and mycelium, along with hot-water versus alcohol extraction, can affect what is concentrated (Memorial Sloan Kettering Cancer Center, 2023). That variability helps explain why “reishi works for everyone” is not a responsible statement.
The Fatigue Signal
In a randomized, double-blind, placebo-controlled trial in 132 patients with neurasthenia, participants used an aqueous polysaccharide extract derived from reishi (Ganoderma lucidum) fruiting bodies for 8 weeks. Compared with placebo, the reishi group showed greater improvements in fatigue scores and sense of well-being by day 56 (Tang et al., 2005).
The important detail for real-world expectations is timing. This was not a one-dose “feel zen” effect. It required consistent daily use over two months (Tang et al., 2005). If you're trialing reishi for fatigue, test it as a habit rather than as a stimulant.
The Metabolic Letdown
Many consumers buy reishi hoping it will improve blood sugar, cholesterol, or metabolic syndrome markers. However, a high-quality 16-week double-blind RCT in adults with type 2 diabetes and metabolic syndrome found no meaningful improvements in HbA1c, fasting glucose, lipids, or blood pressure with Ganoderma lucidum, with or without Cordyceps, compared with placebo (Klupp et al., 2016).
Reishi is useless. It is that reishi should be positioned as a tool for fatigue and resilience, not a metabolic shortcut. If your goal is metabolic health, fiber intake, movement, sleep regularity, and clinician-guided care remain the highest-return levers (Klupp et al., 2016).
Reishi and the Liver: Why Both “Support” and “Risk” Can Be True
It is reasonable to wonder why reishi is sometimes described as supportive for liver health while rare liver injury reports also exist. The key is the evidence type. Reviews summarize multiple preclinical studies in which Ganoderma lucidum compounds show antioxidative, anti-inflammatory, and metabolic effects in liver models (Ahmad et al., 2023). That supports biological plausibility, but it does not prove the treatment of liver disease in humans.
On the other hand, rare cases of clinically apparent liver injury associated with reishi products have been documented, which is why reputable safety resources advise caution and emphasize product quality and monitoring (LiverTox, 2024). In practice, liver support and rare hepatotoxicity can coexist, just as they can with many botanicals.
How to Reduce Liver Risk and Still Use Reishi Confidently
A pro-reishi approach is not to deny rare risk. It is to manage it with sensible guardrails (LiverTox, 2024).
· Prefer food-like use, such as tea or decoction, or moderate-dose single-ingredient products before high-dose stacks.
· Choose transparent products that disclose species, part used, extraction method, and third-party testing (Memorial Sloan Kettering Cancer Center, 2023).
· Avoid polyherbal stacks when starting. If something goes wrong, you will not know what caused it.
· Screen higher-risk users, including those with existing liver disease, heavy alcohol use, or multiple potentially hepatotoxic medications or supplements, and consider baseline labs in practitioner settings (LiverTox, 2024).
· Use a defined trial window of 6 to 8 weeks and reassess. This matches the fatigue RCT timeline (Tang et al., 2005).
· Stop quickly and seek care if jaundice, dark urine, severe nausea, itching, or right upper abdominal pain occurs (LiverTox, 2024).
Clinical Note
If you are immunocompromised, have liver disease, are pregnant or breastfeeding, have upcoming surgery, or take anticoagulants or antiplatelets, use clinician guidance before starting reishi (Memorial Sloan Kettering Cancer Center, 2023; LiverTox, 2024). Reishi should complement, not replace, sleep, nutrition, and clinician-directed care.
Practitioner-Recommended Usage Guide
If you want to test reishi for fatigue resilience, keep the experiment clean. Do not add three new supplements in the same week. Pick one goal, such as fatigue or well-being, hold other variables steady, such as sleep timing and caffeine, and track a simple fatigue score weekly.
Dose and formulation vary by study. The fatigue RCT used a specific polysaccharide extract for 8 weeks (Tang et al., 2005). Metabolic outcomes were tested at 3 g/day in a 16-week RCT with null results (Klupp et al., 2016). Short-term tolerability in healthy adults was evaluated over 10 days in a small RCT (Wicks et al., 2007).
Safety and Interactions
Short-term tolerability has been reported in a small healthy volunteer RCT, but long-term safety remains less certain (Wicks et al., 2007). Potential interactions include additive bleeding risk with anticoagulants and antiplatelets, as well as possible additive effects with antihypertensives or glucose-lowering therapies (Memorial Sloan Kettering Cancer Center, 2023). Rare reports of liver injury reinforce the importance of stopping promptly if warning signs occur (LiverTox, 2024).
FAQ
What is the most evidence-based benefit of reishi in humans?
The clearest RCT signal is improved fatigue and sense of well-being in neurasthenia over 8 weeks using a polysaccharide extract (Tang et al., 2005).
Does reishi reliably lower blood sugar or cholesterol?
Not based on the highest-quality RCT evidence in diabetes and metabolic syndrome, which found no meaningful improvements in glycemia, lipids, or blood pressure (Klupp et al., 2016).
If rare liver injury is reported, how can consumers and practitioners reduce risk?
Use single-ingredient, transparent products, avoid stacking botanicals, consider baseline and follow-up liver enzymes in higher-risk users, and stop promptly if symptoms like jaundice or dark urine occur (LiverTox, 2024; Memorial Sloan Kettering Cancer Center, 2023).
Does reishi support liver health?
Preclinical studies summarized in reviews suggest hepatoprotective pathways, but human clinical outcomes for liver disease are not established. Use supportive language and avoid treatment claims (Ahmad et al., 2023).
How long should I try reishi before deciding whether it helps?
The best fatigue trial lasted 8 weeks, so a consistent 6- to 8-week trial window is a reasonable, evidence-based approach (Tang et al., 2005).
Limitations and Research Gaps
Reishi studies vary by preparation, dose, and population, limiting generalizability. The fatigue RCT was conducted in neurasthenia and may not map perfectly to everyday stress (Tang et al., 2005). Metabolic claims are weakened by a strong null RCT in diabetes and metabolic syndrome (Klupp et al., 2016). More standardized trials with longer safety follow-up would improve confidence (Wicks et al., 2007).
References
1. Ahmad, M. F. (2023). Ganoderma lucidum: Novel insight into hepatoprotective effects. Molecules, 28(9), 3790. https://pmc.ncbi.nlm.nih.gov/articles/PMC10146730/
2. Klupp, N. L., Kiat, H., Bensoussan, A., Steiner, G. Z., & Chang, D. H. (2016). A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Scientific Reports, 6, 29540. https://doi.org/10.1038/srep29540
3. LiverTox. (2024). Lingzhi, reishi. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK609014/
4. Memorial Sloan Kettering Cancer Center. (2023). Reishi mushroom. MSKCC Integrative Medicine. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/reishi-mushroom
5. Tang, W., Gao, Y., Chen, G., Gao, H., Dai, X., Ye, J., Chan, E., Huang, M., & Zhou, S. (2005). A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of Medicinal Food, 8(1), 53–58. https://doi.org/10.1089/jmf.2005.8.53
6. Wanmuang, H., Leopairut, J., Kositchaiwat, C., Wananukul, W., Bunyaratvej, S., & Lapisatepun, W. (2007). Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. Journal of the Medical Association of Thailand, 90(1), 179–181. https://pubmed.ncbi.nlm.nih.gov/17621752/
7. Wicks, S. M., Tong, R., Wang, C.-Z., O’Connor, M., Karrison, T., Li, S., Moss, J., & Yuan, C.-S. (2007). Safety and tolerability of Ganoderma lucidum in healthy subjects: A double-blind randomized placebo-controlled trial. The American Journal of Chinese Medicine, 35(3), 407–414. https://doi.org/10.1142/S0192415X07004928